We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Panels Give Amgen's T-Vec Melanoma Immunotherapy Injection a Thumbs Up
FDA Panels Give Amgen's T-Vec Melanoma Immunotherapy Injection a Thumbs Up
Two FDA advisory committees voted late Wednesday to recommend approval of Amgen’s talimogene laherparepvec immunotherapy for patients with metastatic melanoma, overriding FDA reviewers’ concerns that results from a pivotal clinical trial were skewed.